TRAMP - Construction, Characterization and Pathology 1. Greenberg, N.M., DeMayo, F.J. , Sheppard, P.C., Barrios, R.,Lebovitz, R.,Finegold, M., Angelopoulou, R., Dodd, J.G., Duckworth, M.L., Rosen, J.M. and Matusik, R.J. 1994. The rat probasin gene promoter directs hormonally- and developmentally-regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8:230-239. [PubMed] 2. Greenberg, N.M., DeMayo, F.J., Finegold, M., Medina, D., Tilley, W., J.O. Aspinall, Cunha, G.R., Donjacour, A.A., Matusik, R.J., and Rosen, J.M. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. (USA) 92:3439-3443. [PDF] 3. Gingrich, J.R. and Greenberg, N.M. A transgenic mouse prostate cancer model. 1996. Toxicologic Pathology 24: 502-504. 8. [PubMed] 4. Gingrich, J.R., Barrios, R.J., Morton, R.A., Boyce, B.F., DeMayo, F.J., Finegold, M.J., Angelopoulou, R., Rosen, J.M., and Greenberg, N.M. 1996. Metastasic prostate cancer in a transgenic mouse. Cancer Research 56: 4096-4102.[PubMed] [PDF] 5. Greenberg, N.M. Transgenic models for prostate cancer research. 1996. Urologic Oncology 2: 119-122. 6. Hsu, C.X., Ross, B.D., Chrisp, C.E., Derrow, S.Z., Charles, L.G., Pienta, K.J., Zheng, Z., Greenberg, N.M. and Sanda, M.G. 1998. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J. Urology 160(4):1500-1505 [PubMed] 7. Gingrich, J., Barrios, R.J. Foster, B.A. and Greenberg, N.M. 1999. Pathologic Progression of Autochthonous Prostate Cancer in the TRAMP. . Prostate Cancer and Prostatic Diseases 2:70-75 [PDF] 8. Pu, Y-S., Luo, W., Lu, H-H., Greenberg, N.M. and Lin, S-H. 1999. Differential Expression of C-CAM Cell Adhesion Molecule in Prostate Carcinogenesis in a Transgenic Mouse Model. J. Urology 162:892-896 9. Schatten, H., Allison M.D., Wiedemeiera, A.M., Taylor M., Lubahn, D.B., Greenberg, N.M., Besch-Williford, C., Rosenfeld, C.S., Day, J.K. and , M. 2000. Centrosome - centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell 92:331-340. [PDF] 10. Bruckheimer, EM, Brisbay, S., Johnson, DJ., Gingrich, JR., Greenberg, N., and McDonnell, T.J. 2000. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 19:5251-5258. [PDF] 11. Kwabi-Addo, B, Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N. and Ittmann, M. 2001. Haploinsufficiency of the PTEN tumor suppressor gene promotes tumor progression. Proc. Natl. Acad. Sci, USA 98(20):11563-11568. [PDF] 12. Leman, E.S., Arlotti, J.A., Dahir, R. Greenberg, N. and Getzenberg, R.H. 2002. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer. Journal of Cellular Biochemistry 86:203?212. [PDF] 13. Uzgare, A.R., Kaplan, P.J. and Greenberg, N.M. 2003. Differential Expression and Activation of p38 and Erk MAP Kinase during Initiation and Progression of Prostate Cancer. The Prostate 55:128-139. [PDF] 14. Kaplan-Lefko, P.J., Chen, M-T., Ittmann, M.M., Barrios, R.J., Ayala, G.E., Huss, W.J., Maddison, L.A., Foster, B.A. and Greenberg, N.M. 2003. Pathobiology of Autochthonous Prostate Cancer in a Pre-Clinical Transgenic Mouse Model. The Prostate 55:219-237. [Article PDF] [HiRes Graphics PDF] 15. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer and Prostatic Disease 6(3): 204 –211, 2003 [PDF] 16. Maddison, L.A. and Greenberg, NM. 2003. Differential expression of cell cycle regulatory molecules and evidence for a “cyclin switch” during progression of prostate cancer. The Prostate (in press; e-published Nov 20, 2003) [PDF] TRAMP - Polypeptide Growth Factors and Prostate Cancer 1. Kaplan, PJ., Mohan, S., Cohen, P., Foster, B.A., and Greenberg, N.M. 1999. The insulin-like growth factor axis and prostate cancer: Lessons from TRAMP. Cancer Research 59:2203-2209. [PDF] 2. Foster, B.F, Kaplan, P.J. and Greenberg, N.M. 1999. Changes in the Expression of FGF-7, FGF-10 and a Novel FGFR1iiicF Splice Form Correlate with Prostate Cancer Progression in the TRAMP Model. Prostate Cancer and Prostatic Diseases 2:76-82. [PDF] 3. Foster, B.A., Kaplan, P.J. and Greenberg, N.M. 1999. Peptide Growth Factors and Prostate Cancer: New Models, New Opportunities. Cancer and Metastasis Reviews 17:317-324. [PDF] 4. Huss, W.J., Hanranhan, C., Barrios, R., Simons, J.W., and Greenberg, N.M. 2001. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Research 61: 2736-2743.[PDF] 5. Huss, W.J., Barrios and Greenberg, N.M. 2003. Differential Expression of Specific FGF Ligand and Receptor Isoforms During Angiogenesis Associated With Prostate Cancer Progression. The Prostate 54: 8-16 [PDF] 6. Polnaszek, N., Kwabi-Addo, B., Peterson, L., Ozen, M., Greenberg, NM, Ortega, S., Basilico, C., and Ittmann, M. 2003. FGF2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Research 63: 5754-5760. [PDF] 7. Foster, B.A, Evangelou, A., Gingrich, J.R., DeMayo, F.J., and Greenberg, N.M. 2002. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 70: 624-632. [PDF] 8. Freeman, K.W., Gangula, R.D., Welm, B.E., Ozen, M., Foster, B.A., Rosen, J.M., Ittmann, M., Greenberg, N.M., and Spencer, D.M. 2003. Conditional activation of FGFR1, but not FGFR2, in prostate cancer cells, leads to increased OPN induction, ERK activation and in vivo proliferation. Cancer Research 63: 6237-6243.[PDF] 9. Freeman, K.W., Welm, B.E., Gangula, R.D., Rosen, J.M., Ittmann, M., Greenberg, N.M. and Spencer, D.M. 2003. Inducible prostate neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Research 63:8256-8263 [PDF] TRAMP - Androgen Axis and Prostate Cancer 1. Gingrich, J.R., Barrios, R.J. Kattan, M.W., Nahm, H.S., Finegold, M.J. and Greenberg, N.M. 1997. Androgen independent prostate cancer progression in the TRAMP model. Cancer Research 57:4687-4691. 2. Eng, M.H., Charles, L.G., Ross, B.D., Chrisp, C.E., Pienta, K.J., Greenberg, N.M., Hsu, C.X. and Sanda, M.G. 1999. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 54: 1112-1119. 3. Han, G., Foster, B.A., Mistry, S., Buchanan, G., Harris, J.M., Tilley, W.D. and Greenberg, NM. 2001. Hormone status selects for spontaneous androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J. Biol. Chem 276: 11204-11213. [PDF] 4. Buchanan, G., Yang, M., Nahm, H.S., Han, G., Bentel, J.M., Matusik, R.J., Horsfall, D., Marshall. V.R., Greenberg, N.M. and Tilley, W.D. 2001. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol. 15:46-56. [PDF] 5. Buchanan, G., Greenberg, N.M., Scher, H.I., Harris, J.M., Marshall, V.R. and Tilley, W.D. 2001. Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 7: 1273-1281. [PDF] TRAMP - Immunotherapy 1. Kwon, E.D., Hurwitz, A.A., Foster, B.A., Madias, C., Feldhaus, A.L., Greenberg, N.M., Burg, M.B and Allison, J.P. 1997. Modulation of T cell costimulation and inhibition for immunotherapy of prostate cancer. Proc Natl Acad Sci (USA) 94:8099-8103. [PDF] 2. Kwon, E.D., Foster, B.A., Hurwitz, A.A., Madias, C., Allison, J.P., Greenberg, N.M. and Burg, M.B. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. PNAS (USA) 96:15074-15079. [PDF] 3. Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A. 1999. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol Apr;29(4):1127-38 [PDF] Hurwitz, A.A., Foster, B.A. Kwon, E,D., Truong, T., Choi, E.M., Greenberg, N.M., Burg, M., and Alison, J.P. 2000. Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade. Cancer Research 60:2444-2448. [PDF] 4. Allison, J.P., Hurwitz, A.A., Van Elsa, A., Kwon, E., Sullivan, T., Foster, B and Greenberg, N. 2000. CTLA-4 blockade in tumor immunotherapy. In: Principle and Practice of the Biologic Therapy of Cancer 3rd Ed. (S. Rosenberg ed., Lippincott Williams & Wilkins,) pp-890-895. 5. Hill, R.E., De Avila, D.M., Bertrand, K.P., Greenberg, N.M. and Reeves, J. 2003. Immunization Against Leutinizing Hormone Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer In The Transgenic Adenocarcinoma Mouse Prostate Model. Exp. Biol. Med. 228: 818-822.[PDF] TRAMP - Pre-Clinical Trials 1. Wechter, W.J., Leipold, D.D., Murray, D. Jr., Quiggle, D., McCracken, J.D., Barrios, R.S. and Greenberg, N.M. 2000. E-7869 (R-flubriprofen) inhibits progression of prostate cancer in the TRAMP model. Cancer Research 60: 2203-2208. [PDF] 2. Raghow, S., Steakley, M., Greenberg, N. and Steiner, M.S. 2000. Efficacious Chemoprevention of Primary Prostate Cancer by Flutamide in an Autochthonous Transgenic Model. Cancer Res 60: 4093-4097. [PDF] 3. Gupta, S., Ahmad, N., MacLennan, G.T., Greenberg, N.M. and Mukhtar, H. 2000. Chemoprevention of prostate carcinogenesis by alpha-diflouromethylornithine in TRAMP mice. Cancer Research 60: 5125-5133. [PDF] 4. Shariat, S.F., Desai, S., Song, W., Khan, T., Xiao, J., Nguyen, C., Foster, B.A., Greenberg, N., Spencer, D.M., and Slawin, K.M. 2001. Adenoviral mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Research 61: 2562-2571.[PDF] 5. Mentor-Marcel, R., Lamartiniere, C., Eltoum, I.-E, Greenberg, N.M., and Elgavish, A. 2001. Genestein in the diet reduces the incidence of prostate tumors in a transgenic mouse(TRAMP). Cancer Research 61: 6777-6782. [PDF] 6. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E. 2002. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci (USA) 99(3):1527-1531. [PDF] 7. Shah, A.H., Tabayoyong, T., Kundu, S.D., Kim, S-J., Parijs, L.K., Liu, V.C., Kwon, E., Greenberg, N.M. and Lee, C. 2002. Suppression of tumor metastasis by blockade of transforming growth factor ß signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Research 62:7135-7138. [PDF] 8. Huss, W.J., Barrios and Greenberg, N.M. 2003. SU5416 Impairs Angiogenesis to Induce Prostate Cancer-specific Apoptosis. Molecular Cancer Therapeutics 2:611-616.[PDF] TRAMP - Reviews 1. Green, J.E. and Greenberg, N.M., Ashendel, C.L., Barrett, J.C., Boone, C., Getzenberg, R.H., Henken, J., Matusik, R., Janus, T.J. and Scher, H.I. Transgenic and Reconstitution Animal Models of Prostate Cancer. 1998. The Prostate, 36:59-63. 2. Greenberg, N.M. 2000. Androgens and growth factors in prostate cancer: a transgenic perspective. Prostate Cancer and Prostatic Diseases 3: 224-228. [PDF] 3. Huss, W.J., Maddison, L.A. and Greenberg, N.M. 2001. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001 Jun;11(3):245-60 [PDF] 4. Winter, S., Cooper, A., and Greenberg, N.M. 2003. Models of Metastatic Prostate Cancer: A Transgenic Perspective. Prostate Cancer and Prostatic Disease 6(3): 204 –211. [PDF] TRAMP-C - Cell Lines for Prostate Cancer Research 1. Foster, B., Gingrich, J.R., Kwon, E.D, Madias, C. and Greenberg, N.M. 1997. Characterization of prostatic epithelial cell lines derived from Transgenic adenocarcinoma mouse prostate (TRAMP) model. Cancer Research 57: 3325-3330. [PDF] 2. Ghosh PM, Stapleton ML, Mott GE, Ghosh-Choudhury N, Thomas CA, Foster BA, Greenberg NM, and Kreisberg JI: 1999. Role of RhoA activation and actin stress fiber formation in the growth of a murine prostate tumor cell line. Oncogene 18:4120-4130. 3. Kassis, J., Moellinger, J., Lo, H., Greenberg, N., Kim, H-G., and Wells, A. 1999. A role for PLC gamma-mediated signaling in tumor cell invasion. Clinical Cancer Research 5:2251-2260. [PDF] 4. Chen, Li-Mei, Byron Hodge, G., Guarda, L.A., Welch, J.L., Greenberg, N.M., and Chai, K.X. 2001. Down regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. The Prostate 48: 93-103 [PDF] PB-CRE - Construction and Characterization 1. Maddison, L., Nahm, H., DeMayo, F. and N.M. Greenberg. 2000. Prostate Specific Expression of Cre Recombinase in Transgenic Mice. genesis 26:154-156. [PDF] PB-CRE - Conditional Models 1. Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., di Cristofano, A.D., Xiao, A., Brunet, A., Roy-Burman, P., Greenberg, N.M., Van Dyke, T., Cordon-Cardo, C. and Pandolfi, P.P. 2003. Pten dose dictates cancer progression in the prostate. Public Library of Science (Plos) Volume 1(3):002-012 [PDF]